jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

Scalp mass - Large Biopsy 3-6 cm

Biopsy
image

Report in 288Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Histopathology of scalp lesions.

₹666₹951

30% OFF

Scalp Mass - Large Biopsy 3-6 cm

  • Why is it done?
    • Obtains tissue samples from scalp masses measuring 3-6 cm for histopathological examination and definitive diagnosis
    • Evaluates suspicious lesions, growths, or masses on the scalp that cannot be diagnosed clinically or by imaging alone
    • Determines whether scalp lesions are benign (cysts, lipomas, hemangiomas) or malignant (melanoma, squamous cell carcinoma, basal cell carcinoma, lymphomas)
    • Assesses dermatological conditions requiring tissue confirmation such as fungal infections, inflammatory disorders, or genetic skin conditions
    • Indicated when lesions have concerning features: rapid growth, color variation, irregular borders, bleeding, or ulceration
    • Performed when mass persists despite conservative treatment or when imaging suggests malignancy
  • Normal Range
    • This is a histopathological biopsy procedure; results are primarily qualitative rather than quantitative
    • Normal/Benign Result: Tissue shows normal histological architecture with no evidence of malignancy, abnormal cells, or disease pathology
    • Benign Findings: Lipoma, epidermoid cyst, pilomatrixoma, hemangioma, seborrheic keratosis, or other non-cancerous lesions
    • Abnormal/Malignant Result: Presence of atypical cells, malignant transformation, or confirmed cancer diagnosis
    • Specimen Quality: Adequate tissue sample typically obtained in specimens of 3-6 cm, ensuring sufficient material for comprehensive histological analysis
  • Interpretation
    • Benign Lesions: Reassuring diagnosis with no cancer risk; typical findings include normal dermal tissue, fat (lipoma), or cyst wall composition. No further oncologic treatment typically required.
    • Malignant Lesions: Confirms cancer diagnosis; grade and stage determined by histological examination. Requires immediate oncologic management and further staging studies.
    • Melanoma Findings: Breslow thickness, mitotic rate, ulceration status, and lymphocytic infiltration are measured to determine prognosis and treatment strategy
    • Non-melanoma Skin Cancer: Squamous cell carcinoma and basal cell carcinoma grades and subtypes defined; perineural invasion noted as significant finding affecting prognosis
    • Atypical/Borderline Findings: May indicate dysplasia or precancerous changes requiring close clinical follow-up and possibly repeat biopsy or wider excision
    • Infectious/Inflammatory Findings: May reveal fungal organisms, granulomatous inflammation, or autoimmune skin conditions requiring targeted medical therapy
    • Factors Affecting Interpretation: Specimen orientation, fixation adequacy, crushing artifact, cautery effect, and immunohistochemical staining may all impact accuracy
  • Associated Organs
    • Primary Organ System: Integumentary system (skin and associated structures); scalp tissue includes epidermis, dermis, and subcutaneous fat
    • Benign Conditions Identified: Sebaceous cysts, epidermoid cysts, lipomas, angiomas, pilomatrixomas, fibrous hyperplasias, and keloid formations
    • Malignant Conditions Identified: Melanoma, squamous cell carcinoma, basal cell carcinoma, Merkel cell carcinoma, cutaneous lymphomas, and metastatic disease to scalp
    • Associated Systemic Conditions: Malignant findings may indicate systemic disease requiring evaluation of lymph nodes, liver, lungs, and bone; potential for metastatic spread
    • Complications Related to Abnormal Results: Cancer diagnosis may necessitate wide surgical excision, chemotherapy, radiation therapy, or immunotherapy; significant cosmetic and functional implications for scalp lesions
    • Neurological Considerations: Scalp masses may involve cranial nerves; perineural invasion by malignancy creates specific treatment challenges and prognostic concerns
  • Follow-up Tests
    • If Malignancy Confirmed: Complete physical examination, sentinel lymph node biopsy for melanomas, imaging studies (CT, MRI, or PET scan) for staging and metastatic evaluation
    • Immunohistochemical Staining: May be performed on biopsy tissue to confirm diagnosis, determine tumor markers, and guide targeted therapy selection
    • Genetic/Molecular Testing: BRAF mutation analysis, microsatellite instability testing, and other molecular markers for melanoma and other skin cancers to guide treatment
    • Sentinel Lymph Node Surgery: Indicated for melanomas >1 mm Breslow thickness or other high-risk features to stage disease and guide adjuvant therapy
    • Imaging Studies: Brain MRI, chest CT, abdominal/pelvic imaging for melanomas and other high-risk skin cancers; whole body PET scan for metastatic evaluation
    • Dermatology/Oncology Referral: Specialist consultation recommended for all malignant findings; multidisciplinary care team for treatment planning and ongoing management
    • Clinical Monitoring: Regular skin examinations every 3-6 months for benign lesions; monthly skin checks for melanoma history; screening for recurrence or new lesions
    • Wide Local Excision: Definitive surgical treatment recommended for confirmed malignancies; margins determined by tumor type and stage
    • If Infectious/Inflammatory Process: Fungal culture and sensitivity, special stains (PAS, GMS), bacterial culture if indicated; serology for specific infections; evaluation for systemic involvement
  • Fasting Required?
    • Fasting Requirement: No - Fasting is not required for this biopsy procedure
    • Pre-procedure Preparation: Patients may eat and drink normally; normal medications may be continued; light meal prior to procedure is acceptable
    • Medication Considerations: Discontinue anticoagulants (warfarin) 3-5 days before procedure if possible; hold aspirin and NSAIDs for 7-10 days prior; notify physician of all current medications
    • Skin Preparation: Wash scalp gently with soap and water morning of procedure; no makeup, lotions, or styling products on scalp; hair may be slightly damp
    • Anesthesia: Local anesthesia used for biopsy; no sedation required; patient remains alert during procedure
    • Imaging/Ultrasound: Ultrasound may be performed prior to biopsy to assess mass characteristics and guide needle placement; no preparation required
    • Post-procedure Instructions: Avoid strenuous activity for 24 hours; keep biopsy site clean and dry; apply antibiotic ointment as directed; avoid shampooing for 3-5 days; minimal bleeding expected with light pressure if needed
    • Results Timeline: Preliminary histopathology results typically available in 3-5 business days; special stains and immunohistochemistry may require additional 5-7 days; complex cases may extend to 2-3 weeks

How our test process works!

customers
customers